Taibi C, Tempestilli M, D'Avolio A, Garbuglia A R, De Nicolò A, Montalbano M, D'Offizi G
National Institute for Infectious Diseases "L. Spallanzani" I.R.C.C.S., Rome, Italy.
Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy.
J Clin Pharm Ther. 2017 Oct;42(5):621-623. doi: 10.1111/jcpt.12546. Epub 2017 May 4.
The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients.
We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment.
This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
第二代直接作用抗病毒药物几乎在所有患者群体中代表了根除丙型肝炎病毒感染的首个重大转折点。然而，尚无关于胃切除患者使用情况的数据。
我们报告了一名接受胃切除的慢性丙型肝炎感染患者。她接受了索磷布韦和来迪帕司韦（SOF/LDV）治疗12周，并检测了药物的血药浓度。她在第12周和第24周时未经剂量调整获得了持续病毒学应答。
本病例报告可为该类患者的临床实践提供有用信息，并为评估索磷布韦/来迪帕司韦的实际生物利用度开辟新的视角。
